Stender Diagnostics
Gentofte
About Stender Diagnostics
Bloodstream infections (BSI) are curable with off-the-shelf antibiotics - but only if the pathogen causing the infection is accurately identified early on. If not, BSI can quickly develop into sepsis, which only approx. 50% of patients survive - and which one of the most expensive conditions to treat because patients require intensive care unit (ICU) support for 7-14 days, and average hospital length of stay for survivors is 3-5 weeks. A rapid and accurate test for BSI is not available today and is considered the holy grail of diagnostics. The market for such a test is estimated to be worth 1 billion USD a year. Stender Diagnostics has taken important and validated steps towards the development and regulatory approval of such a test. AntibioDx is a unique in vitro diagnostic test for rapid and accurate identification of pathogens in the bloodstream. The AntibioDx device delivers the information doctors need when they need it - which is within 1 hour of suspecting a bloodstream infection (BSI). AntibioDx will remove the guesswork from the clinical decision-making process and will ensure doctors make the right decision, both in terms of whether to treat and how to treat. Both money and lives will be saved.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $56.5K
- Last round: Grant (Sep 2015)
- Website: stenderdiagnostics.com
- Phone: (+45) 22 37 47 75
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/stender-diagnostics-672603 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.